论文部分内容阅读
目的观察及分析甲氨蝶呤与来氟米特治疗类风湿性关节炎的临床疗效和安全性。方法 92例类风湿性关节炎患者,随机分为对照组及实验组,各46例。对照组采用甲氨蝶呤治疗,实验组采用甲氨蝶呤与来氟米特治疗。对比两组患者的临床疗效、关节肿胀数、关节痛数及晨僵时间及不良反应发生率。结果治疗后,实验组总有效率为97.8%,高于对照组的82.6%(P<0.05)。实验组关节肿胀数、关节痛数及晨僵时间均优于对照组,差异均有统计学意义(P<0.05)。实验组不良反应发生率为8.70%,与对照组的4.34%比较,差异无统计学意义(P>0.05)。结论甲氨蝶呤与来氟米特治疗类风湿性,可取得满意疗效,且具备很高的安全性,建议大力推广及应用。
Objective To observe and analyze the clinical efficacy and safety of methotrexate and leflunomide in the treatment of rheumatoid arthritis. Methods 92 cases of rheumatoid arthritis patients were randomly divided into control group and experimental group, each 46 cases. The control group methotrexate treatment, the experimental group methotrexate and leflunomide treatment. The clinical efficacy, joint swelling, joint pain, morning stiffness and the incidence of adverse reactions were compared between the two groups. Results After treatment, the total effective rate of the experimental group was 97.8%, which was higher than that of the control group (82.6%, P <0.05). The number of joint swelling, joint pain and morning stiffness in the experimental group were better than those in the control group, with significant differences (P <0.05). The incidence of adverse reactions in the experimental group was 8.70%, compared with 4.34% in the control group, the difference was not statistically significant (P> 0.05). Conclusion Methotrexate and leflunomide treatment of rheumatoid, can be obtained with satisfactory results, and with high safety, it is recommended to promote and application.